DK2131860T3 - Anti-sclerostin-antistoffer - Google Patents

Anti-sclerostin-antistoffer

Info

Publication number: DK2131860T3
Authority: DK; Denmark
Prior art keywords: sclerostin antibodies; sclerostin; antibodies
Prior art date: 2007-03-20

Application number

DK08731905.9T

Other languages

English (en)

Inventor

Andrew Ihor Korytko

David Matthew Marquis

Eric Michael Smith

Barbara Anne Swanson

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-03-20

Filing date

2008-03-11

Publication date

2014-01-13

2008-03-11 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2014-01-13 Application granted granted Critical

2014-01-13 Publication of DK2131860T3 publication Critical patent/DK2131860T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Physical Education & Sports Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Pain & Pain Management (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

DK08731905.9T 2007-03-20 2008-03-11 Anti-sclerostin-antistoffer DK2131860T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US89581307P	2007-03-20	2007-03-20
PCT/US2008/056527 WO2008115732A2 (en)	2007-03-20	2008-03-11	Anti-sclerostin antibodies

Publications (1)

Publication Number	Publication Date
DK2131860T3 true DK2131860T3 (da)	2014-01-13

Family

ID=39756356

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK08731905.9T DK2131860T3 (da)	2007-03-20	2008-03-11	Anti-sclerostin-antistoffer

Country Status (31)

Country	Link
US (3)	US7744874B2 (da)
EP (2)	EP2131860B1 (da)
JP (2)	JP2010524846A (da)
KR (1)	KR101123487B1 (da)
CN (1)	CN101646457B (da)
AU (1)	AU2008229141B2 (da)
BR (1)	BRPI0809026A2 (da)
CA (1)	CA2682212C (da)
CO (1)	CO6230999A2 (da)
CR (1)	CR11004A (da)
CY (1)	CY1114784T1 (da)
DK (1)	DK2131860T3 (da)
DO (1)	DOP2009000223A (da)
EA (1)	EA018204B1 (da)
EC (1)	ECSP099658A (da)
ES (1)	ES2446293T3 (da)
HR (1)	HRP20140108T1 (da)
IL (1)	IL200437A0 (da)
MA (1)	MA31308B1 (da)
MX (1)	MX2009010051A (da)
MY (1)	MY149129A (da)
NZ (1)	NZ578870A (da)
PL (1)	PL2131860T3 (da)
PT (1)	PT2131860E (da)
RS (1)	RS53157B (da)
SI (1)	SI2131860T1 (da)
SV (1)	SV2009003374A (da)
TN (1)	TN2009000383A1 (da)
UA (1)	UA96474C2 (da)
WO (1)	WO2008115732A2 (da)
ZA (1)	ZA200906345B (da)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040009535A1 (en) *	1998-11-27	2004-01-15	Celltech R&D, Inc.	Compositions and methods for increasing bone mineralization
ES2639020T3 (es)	1998-11-27	2017-10-25	Ucb Pharma S.A.	Composiciones y métodos para incrementar la mineralización de la substancia ósea
CN1835974A (zh)	2003-06-16	2006-09-20	细胞技术研究与发展公司	对硬化素特异的抗体和用于增加骨矿化的方法
US8461155B2 (en) *	2003-09-22	2013-06-11	University Of Connecticut	Sclerostin and the inhibition of WNT signaling and bone formation
US7592429B2 (en)	2005-05-03	2009-09-22	Ucb Sa	Sclerostin-binding antibody
US8003108B2 (en)	2005-05-03	2011-08-23	Amgen Inc.	Sclerostin epitopes
SI3345607T1 (sl)	2006-12-29	2023-03-31	Ossifi-Mab Llc	Postopki spreminjanja rasti kosti z dajanjem antagonista ali agonista SOST ali WISE
EP2131860B1 (en) *	2007-03-20	2013-12-18	Eli Lilly & Company	Anti-sclerostin antibodies
CL2008002775A1 (es) *	2007-09-17	2008-11-07	Amgen Inc	Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AR068767A1 (es) *	2007-10-12	2009-12-02	Novartis Ag	Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
AU2008338464A1 (en) *	2007-12-14	2009-06-25	Amgen Inc.	Method for treating bone fracture with anti-sclerostin antibodies
AR070141A1 (es) *	2008-01-23	2010-03-17	Glenmark Pharmaceuticals Sa	Anticuerpos humanizados especificos para el factor von willebrand
TW201920257A (zh)	2008-04-11	2019-06-01	日商中外製藥股份有限公司	重複結合複數個抗原的抗原結合分子
WO2010115932A1 (en)	2009-04-08	2010-10-14	Novartis Ag	Combination for the treatment of bone loss
MX2012011629A (es)	2010-04-07	2013-03-05	Abbvie Inc	Proteinas de union a tnf-alfa.
EP2558106A1 (en)	2010-04-16	2013-02-20	Novartis AG	Methods and compositions for improving implant osseointegration
SMT202000095T1 (it)	2010-05-14	2020-03-13	Amgen Inc	Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
CA2802376A1 (en)	2010-06-14	2011-12-22	Vaccinex, Inc.	Anti-vegf antibodies and uses thereof
AU2011325134B2 (en)	2010-11-05	2014-10-23	Novartis Ag	Methods of treating rheumatoid arthritis using IL-17 antagonists
JP5319651B2 (ja) *	2010-11-18	2013-10-16	日本電信電話株式会社	分析方法
TWI654203B (zh)	2010-11-30	2019-03-21	Chugai Seiyaku Kabushiki Kaisha	具有鈣依存性的抗原結合能力之抗體
EP3252076B1 (en)	2011-01-14	2019-09-04	The Regents Of The University Of California	Diagnostic use of antibodies against ror-1 protein
JP2014509588A (ja)	2011-03-01	2014-04-21	アムジエン・インコーポレーテツド	二特異性結合剤
US9145457B2 (en)	2011-03-25	2015-09-29	Amgen Inc.	Sclerostin antibody crystals and formulations thereof
ES2823240T3 (es)	2011-04-19	2021-05-06	Amgen Inc	Método para el tratamiento de la osteoporosis
US20140056912A1 (en)	2011-04-29	2014-02-27	Novartis Ag	Methods of treating squamous cell carcinoma
ES2667554T3 (es)	2011-08-04	2018-05-11	Amgen Inc.	Método para el tratamiento de los defectos de espacio óseo
UY34410A (es)	2011-10-24	2013-05-31	Abbvie Inc	Inmunoligantes biespecificos dirigidos contra tnf
AR088513A1 (es) *	2011-10-24	2014-06-18	Abbvie Inc	Inmunoenlazantes dirigidos contra esclerostina
AU2012328921B2 (en)	2011-10-24	2017-05-11	Abbvie Inc.	Immunobinders directed against TNF
KR20190120401A (ko) *	2011-12-28	2019-10-23	암젠 인크	항스클레로스틴 항체의 이용을 통한 치조골 소실의 치료 방법
JP6770312B2 (ja) *	2012-07-05	2020-10-14	ユセベファルマソシエテアノニム	骨疾患の治療
US9221904B2 (en)	2012-07-19	2015-12-29	National Cheng Kung University	Treatment of osteoarthritis using IL-20 antagonists
US20140065144A1 (en) *	2012-08-30	2014-03-06	National Cheng Kung University	Use of il-20 antagonists for promoting bone fracture healing
UY35148A (es)	2012-11-21	2014-05-30	Amgen Inc	Immunoglobulinas heterodiméricas
WO2014118705A1 (en)	2013-01-31	2014-08-07	Novartis Ag	Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists
JOP20140049B1 (ar)	2013-03-08	2021-08-17	Lilly Co Eli	أجسام مضادة ترتبط بـ il-23
WO2014144817A2 (en)	2013-03-15	2014-09-18	Amgen Inc.	Inhibitory polypeptides specific to wnt inhibitors
WO2014155278A2 (en)	2013-03-26	2014-10-02	Novartis Ag	Methods of treating autoimmune diseases using il-17 antagonists
WO2015087187A1 (en)	2013-12-10	2015-06-18	Rinat Neuroscience Corp.	Anti-sclerostin antibodies
US9763911B2 (en)	2013-12-12	2017-09-19	Mayo Foundation For Medical Education And Research	Prostacyclin compositions for regulation of fracture repair and bone formation
AR100270A1 (es) *	2014-05-19	2016-09-21	Lilly Co Eli	Anticuerpos ang2
MA41101A (fr) *	2014-12-03	2017-10-10	Lilly Co Eli	Dispositif d'injection de médicament automatique comportant une indication audible de progression d'injection
MA41142A (fr)	2014-12-12	2017-10-17	Amgen Inc	Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
AR103173A1 (es)	2014-12-22	2017-04-19	Novarits Ag	Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
HK1245154A1 (zh) *	2014-12-30	2018-08-24	细胞基因公司	抗cd47抗体及其用途
WO2016145961A1 (zh) *	2015-03-13	2016-09-22	江苏恒瑞医药股份有限公司	抗硬骨素抗体、其抗原结合片段及其医药用途
RU2756275C2 (ru)	2016-03-01	2021-09-29	Юссум Рисёрч Девелопмент Компани Оф Зэ Хибру Юниверсити Оф Иерусалим Лтд.	Антитела, специфические к рецептору полиовируса (pvr) человека
GB201604124D0 (en)	2016-03-10	2016-04-27	Ucb Biopharma Sprl	Pharmaceutical formulation
MA45921A (fr)	2016-08-08	2019-06-19	Amgen Inc	Procédé d'amélioration de la fixation du tissu conjonctif à l'aide d'anticorps anti-sclérostine.
US10913799B2 (en) *	2016-10-28	2021-02-09	Eli Lilly And Company	Anti-RANKL antibodies and uses thereof
CN110049777A (zh) *	2016-11-01	2019-07-23	安奈普泰斯生物有限公司	针对程序性死亡-1(pd-1)的抗体
AU2017381433B2 (en) *	2016-12-21	2024-11-14	Mereo Biopharma 3 Limited	Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
PT3565844T (pt)	2017-01-09	2023-05-02	Tesaro Inc	Métodos de tratamento de cancro com anticorpos anti-pd-1
WO2018139623A1 (en) *	2017-01-30	2018-08-02	Chugai Seiyaku Kabushiki Kaisha	Anti-sclerostin antibodies and methods of use
US11530240B2 (en)	2017-06-09	2022-12-20	The Regents Of The University Of California	Catheter injectable cyclic peptide pro-gelators for myocardial tissue engineering
KR20200034748A (ko)	2017-07-27	2020-03-31	지앙수 헨그루이 메디슨 컴퍼니 리미티드	Sost 항체 약학적 조성물 및 그의 용도
EP3774879B1 (en)	2018-03-30	2026-01-28	Amgen Inc.	C-terminal antibody variants
GB201810746D0 (en)	2018-06-29	2018-08-15	Mereo Biopharma 3 Ltd	Use of sclerostin antagonist
CA3108693A1 (en)	2018-08-10	2020-02-13	Ashutosh Sharma	Method of preparing an antibody pharmaceutical formulation
WO2020154150A1 (en) *	2019-01-22	2020-07-30	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	High affinity monoclonal antibodies targeting glypican-1 and methods of use
WO2021030179A1 (en)	2019-08-12	2021-02-18	Amgen Inc.	Anti-sclerostin antibody formulations
KR20220082007A (ko)	2019-10-08	2022-06-16	넥틴 테라퓨틱스 리미티드	폴리오바이러스 수용체(pvr)에 대한 항체 및 이의 용도
KR20260040623A (ko)	2023-07-19	2026-03-25	암젠 인크	치료 단백질 제형용 완충제 제조 방법
AU2024357328A1 (en) *	2023-10-12	2026-05-28	The Regents Of The University Of Michigan	Bone targeting therapeutics
CN119097708B (zh) *	2024-09-04	2025-05-09	中国医学科学院北京协和医院	Dkk1单克隆抗体在制备用于治疗骨质疏松症的药物组合物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040009535A1 (en)	1998-11-27	2004-01-15	Celltech R&D, Inc.	Compositions and methods for increasing bone mineralization
ES2639020T3 (es)	1998-11-27	2017-10-25	Ucb Pharma S.A.	Composiciones y métodos para incrementar la mineralización de la substancia ósea
JP2004520005A (ja)	2000-06-19	2004-07-08	エフ．ホフマン−ラ　ロシュ　アーゲー	オステオレビン遺伝子多型性
US20040023356A1 (en)	2002-06-14	2004-02-05	Robb Krumlauf	Wise/Sost nucleic acid sequences and amino acid sequences
WO2004047609A2 (en) *	2002-11-27	2004-06-10	Visiopharm Aps	A method and a system for establishing a quantity measure for joint destruction
CN1835974A (zh)	2003-06-16	2006-09-20	细胞技术研究与发展公司	对硬化素特异的抗体和用于增加骨矿化的方法
EP1644416A4 (en)	2003-06-30	2007-08-29	Centocor Inc	ANTI-TARGET AND GENETICALLY MODIFIED IMMUNOGLOBULIN-DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
EP1853630A1 (en)	2004-10-22	2007-11-14	Applied Molecular Evolution Inc.	Methods of optimizing antibody variable region binding affinity
US7592429B2 (en)	2005-05-03	2009-09-22	Ucb Sa	Sclerostin-binding antibody
US8003108B2 (en)	2005-05-03	2011-08-23	Amgen Inc.	Sclerostin epitopes
US20100036091A1 (en)	2006-11-10	2010-02-11	Amgen Inc.	Antibody-based diagnostics and therapeutics
EP2131860B1 (en) *	2007-03-20	2013-12-18	Eli Lilly & Company	Anti-sclerostin antibodies

2008
- 2008-03-11 EP EP08731905.9A patent/EP2131860B1/en active Active
- 2008-03-11 MY MYPI20093894A patent/MY149129A/en unknown
- 2008-03-11 CA CA2682212A patent/CA2682212C/en not_active Expired - Fee Related
- 2008-03-11 PL PL08731905T patent/PL2131860T3/pl unknown
- 2008-03-11 CN CN2008800091183A patent/CN101646457B/zh active Active
- 2008-03-11 MX MX2009010051A patent/MX2009010051A/es active IP Right Grant
- 2008-03-11 ES ES08731905.9T patent/ES2446293T3/es active Active
- 2008-03-11 PT PT87319059T patent/PT2131860E/pt unknown
- 2008-03-11 BR BRPI0809026-2A2A patent/BRPI0809026A2/pt not_active IP Right Cessation
- 2008-03-11 HR HRP20140108AT patent/HRP20140108T1/hr unknown
- 2008-03-11 RS RS20140033A patent/RS53157B/sr unknown
- 2008-03-11 AU AU2008229141A patent/AU2008229141B2/en not_active Ceased
- 2008-03-11 NZ NZ578870A patent/NZ578870A/en not_active IP Right Cessation
- 2008-03-11 US US12/160,472 patent/US7744874B2/en active Active
- 2008-03-11 JP JP2009554637A patent/JP2010524846A/ja active Pending
- 2008-03-11 UA UAA200909553A patent/UA96474C2/ru unknown
- 2008-03-11 DK DK08731905.9T patent/DK2131860T3/da active
- 2008-03-11 EA EA200970874A patent/EA018204B1/ru not_active IP Right Cessation
- 2008-03-11 EP EP13178615.4A patent/EP2664346A1/en not_active Withdrawn
- 2008-03-11 WO PCT/US2008/056527 patent/WO2008115732A2/en not_active Ceased
- 2008-03-11 SI SI200831127T patent/SI2131860T1/sl unknown
- 2008-03-11 KR KR1020097019509A patent/KR101123487B1/ko not_active Expired - Fee Related
2009
- 2009-08-17 IL IL200437A patent/IL200437A0/en unknown
- 2009-08-28 CR CR11004A patent/CR11004A/es unknown
- 2009-09-10 CO CO09097358A patent/CO6230999A2/es active IP Right Grant
- 2009-09-11 ZA ZA2009/06345A patent/ZA200906345B/en unknown
- 2009-09-18 TN TNP2009000383A patent/TN2009000383A1/fr unknown
- 2009-09-18 DO DO2009000223A patent/DOP2009000223A/es unknown
- 2009-09-18 SV SV2009003374A patent/SV2009003374A/es unknown
- 2009-09-28 EC EC2009009658A patent/ECSP099658A/es unknown
- 2009-10-12 MA MA32274A patent/MA31308B1/fr unknown
2010
- 2010-05-13 US US12/779,438 patent/US7988970B2/en active Active
2011
- 2011-06-21 US US13/165,126 patent/US8257704B2/en active Active
2013
- 2013-02-22 JP JP2013033583A patent/JP5758933B2/ja active Active
2014
- 2014-02-03 CY CY20141100082T patent/CY1114784T1/el unknown

Also Published As

Publication number	Publication date
CN101646457A (zh)	2010-02-10
TN2009000383A1 (en)	2010-12-31
CN101646457B (zh)	2013-05-01
US7988970B2 (en)	2011-08-02
NZ578870A (en)	2012-01-12
DOP2009000223A (es)	2009-10-15
EA018204B1 (ru)	2013-06-28
AU2008229141A1 (en)	2008-09-25
US8257704B2 (en)	2012-09-04
CO6230999A2 (es)	2010-12-20
JP5758933B2 (ja)	2015-08-05
JP2013151504A (ja)	2013-08-08
EA200970874A1 (ru)	2010-02-26
CA2682212A1 (en)	2008-09-25
CY1114784T1 (el)	2016-12-14
MX2009010051A (es)	2009-10-12
EP2664346A1 (en)	2013-11-20
MY149129A (en)	2013-07-15
MA31308B1 (fr)	2010-04-01
EP2131860B1 (en)	2013-12-18
HRP20140108T1 (hr)	2014-02-28
WO2008115732A3 (en)	2008-12-11
RS53157B (sr)	2014-06-30
SV2009003374A (es)	2011-01-10
ECSP099658A (es)	2009-10-30
EP2131860A2 (en)	2009-12-16
US20090060924A1 (en)	2009-03-05
SI2131860T1 (sl)	2014-02-28
PT2131860E (pt)	2014-03-04
HK1138790A1 (en)	2010-09-03
UA96474C2 (en)	2011-11-10
PL2131860T3 (pl)	2014-05-30
KR101123487B1 (ko)	2012-03-23
IL200437A0 (en)	2010-04-29
ZA200906345B (en)	2010-11-24
US20100221263A1 (en)	2010-09-02
US20110250205A1 (en)	2011-10-13
WO2008115732A2 (en)	2008-09-25
CR11004A (es)	2009-11-02
KR20090114462A (ko)	2009-11-03
JP2010524846A (ja)	2010-07-22
BRPI0809026A2 (pt)	2014-09-23
ES2446293T3 (es)	2014-03-07
CA2682212C (en)	2014-05-06
AU2008229141B2 (en)	2013-02-07
US7744874B2 (en)	2010-06-29

Publication	Publication Date	Title
CY2019004I2 (el)	2019-11-27	Τροποποιημενα αντισωματα αντι-ιl-23ρ19
PT2195026E (pt)	2014-03-31	Anticorpos anti-esclerostina
BRPI0819165A2 (pt)	2015-06-23	Anticorpos anti-vegf
BRPI0907532A2 (pt)	2015-07-28	Anticorpos anti-c5ar humanizados
BRPI0923359A2 (pt)	2015-07-21	Anticorpos anti-igf
PL3059246T3 (pl)	2018-11-30	Zmodyfikowany region stały przeciwciała
BRPI0906877A2 (pt)	2015-07-28	Anticorpos anti-trkb aperfeiçoados
IL212175B (en)	2019-08-29	Muc1* antibodies
HRP20171011T1 (hr)	2017-09-22	ANTI-eMET ANTITIJELO
BRPI0907237A2 (pt)	2015-07-14	Anticorpo anti-cldn6
ZA200906345B (en)	2010-11-24	Anti-sclerostin antibodies
DK2066695T3 (da)	2013-06-10	Anti-myostatin-antistoffer
BRPI0821777A2 (pt)	2015-06-16	Anticorpos biespecíficos bivalentes
HUE056626T2 (hu)	2022-02-28	Antitestkészítmény
BRPI0809677A2 (pt)	2014-10-07	Anticorpos anti-ige
NO344963B1 (no)	2020-08-03	Humanisert antistoff
BRPI0922800A2 (pt)	2015-12-22	anticorpos c-met
BRPI0807991A2 (pt)	2014-06-17	Anticorpos anti-il-23r elaborados.
DK2344537T3 (da)	2014-02-10	Bispecifikke anti-vegf/anti-ang-2-antistoffer
HUE038501T2 (hu)	2018-10-29	Antitest készítmények
EP2181121A4 (en)	2012-07-11	CHIMÄRE ANTIGENE
DK2234600T3 (da)	2014-09-08	Antistofformulering
BRPI0821375A2 (pt)	2015-06-16	Anticorpos biespecíficos, bivalentes
BRPI0821405A2 (pt)	2015-06-16	Anticorpos biespecíficos, bivalentes
FI20075278A0 (fi)	2007-04-20	Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet